Targeting serious diseases of
immuno-inflammation and fibrosis
Our lead product candidate cenicriviroc (CVC) is under evaluation to treat non-alcoholic steatohepatitis (NASH) with liver fibrosis and other serious illnesses
NASH is a severe type of non-alcoholic fatty liver disease, or NAFLD. NASH affects 3 to 5 percent of the US population and can lead to life-threatening complications such as cirrhosis and liver cancer. There are no approved therapies for patients suffering from this severe condition.
Tobira is evaluating CVC’s efficacy and safety in multiple clinical studies, including the CENTAUR Study, an international, randomized Phase 2b study of CVC vs placebo in patients with NASH and liver fibrosis (NCT02217475).
Immuno-inflammatory & Fibrosis
- 11.10.15 Tobira Therapeutics Reports Third Quarter 2015 Financial Results
- 11.3.15 Tobira Therapeutics Announces Date of 2015 Third Quarter Financial Results and Conference Call
- 10.1.15 Tobira Therapeutics Announces Presentations Related to Cenicriviroc's Development Program in NASH at the American Association for the Study of Liver Diseases Annual Meeting